Search
Spotlight
In-person and virtual events just for HCPs
In-person and virtual events just for HCPs
Specialty
View More
Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer
Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer
News
OncClub
All Oncology News
OncClub
All Oncology News
Media
Insights
MedNews Week
OncChats
OncLive News Network®
OncLive TV
Peer Exchange
Podcasts
Rapid Readouts
Insights
MedNews Week
OncChats
OncLive News Network®
OncLive TV
Peer Exchange
Podcasts
Rapid Readouts
Conferences
Conference Coverage
Conference Listing
Conference Coverage
Conference Listing
Events
Giants of Cancer Care
CME/CE
Scientific Interchanges
State of the Science Summit / IPC
National Fellows Forum
Webinars
Giants of Cancer Care
CME/CE
Scientific Interchanges
State of the Science Summit / IPC
National Fellows Forum
Webinars
Partners
Publications
Resources
Interactive Tools
Sponsored
Interactive Tools
Sponsored
Biomarker Consortium
Subscribe
Search
Spotlight
In-person and virtual events just for HCPs
Specialty
See All >
Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer
Management of Drug-Induced Interstitial Lung Disease - Episode 6
CDK 4/6 Inhibitors and Identifying ILD in Patients
June 30, 2020
Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center
,
Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center
,
Axel Grothey, MD, West Cancer Center, University of Tennessee
,
Jarushka Naidoo, MBBCh, Sidney Kimmel Cancer Center, Johns Hopkins
,
Tanios Bekaii-Saab, MD, FACP, Mayo Clinic
EP. 1: Antibody Drug Conjugates and Interstitial Lung Disease Risk
EP. 2: Risks for Developing ILD and Personal Experience
EP. 3: Changes in Cancer Treatment and Management of ILD
EP. 4: Use of Antibody Drug Conjugates and Potential for ILD
EP. 5: Rate and Class Effect of ILD with Antibody Drug Conjugates
Now Viewing
EP. 6: CDK 4/6 Inhibitors and Identifying ILD in Patients
EP. 7: Managing Patient Symptoms and Clinician Education
EP. 8: Drug-Induced ILD and Rate of Occurrence in GI Cancer Trials
EP. 9: Patient Factors for Developing ILD and Personal Experience
EP. 10: Patient Management upon Developing ILD and Education
EP. 11: Potential Risk of Drug-Induced Interstitial Lung Disease
EP. 12: Personal Experience with Drug-Induced ILD
EP. 13: Rate of ILD and Monitoring Parameters
EP. 14: Identifying Drug-Induced ILD
EP. 15: Patient Management and Educational Tools for ILD
EP. 16: Role of Antibody Drug Conjugates and Personal Experience
EP. 17: Risks for Developing ILD in Gastrointestinal Cancer Studies
EP. 18: Risk of ILD as a Class Effect and Identifying ILD
EP. 19: Changes in Treatment Goals due to Drug Induced ILD
EP. 20: Management of Patients Who Develop ILD
EP. 21: Educational Tools for Possible Drug-Induced ILD